| 1 0.15 (17.65%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.8 | 1-year : | 5.58 |
| Resists | First : | 3.26 | Second : | 4.78 |
| Pivot price | 2  |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 2.25 |
| MA(100) : | 7.12 |
MA(250) : | 9.33 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 3.8  |
D(3) : | 2.9 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 21.09 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TVGN ] has closed above bottom band by 3.7%. Bollinger Bands are 36.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.22 |
| Low: | 0.91 - 0.92 | 0.92 - 0.93 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Fri, 26 Apr 2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI ... - WDRB
Thu, 18 Apr 2024
TVGN Stock Price and Chart — NASDAQ:TVGN — TradingView - TradingView
Fri, 05 Apr 2024
Tevogen Bio (NASDAQ: TVGN) Secures $6 Million Investment to Advance Immunotherapy Innovations, Signals ... - Coin Standard
Wed, 03 Apr 2024
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development - Markets Insider
Wed, 27 Mar 2024
Tevogen Bio Announces Series A-1 Preferred Stock Investment - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 165 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 102.7 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|